Australia markets closed

Hyloris Pharmaceuticals SA (HYL.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
11.45+0.40 (+3.62%)
At close: 05:35PM CET
Currency in EUR

Valuation measures4

Market cap (intra-day) 320.60M
Enterprise value 291.66M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)113.93
Price/book (mrq)8.26
Enterprise value/revenue 103.65
Enterprise value/EBITDA -19.42

Trading information

Stock price history

Beta (5Y monthly) 0.59
52-week change 3-12.85%
S&P500 52-week change 327.86%
52-week high 314.10
52-week low 310.60
50-day moving average 312.43
200-day moving average 312.05

Share statistics

Avg vol (3-month) 310.73k
Avg vol (10-day) 318.46k
Shares outstanding 528M
Implied shares outstanding 628.63M
Float 8N/A
% held by insiders 156.62%
% held by institutions 10.48%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-548.55%

Management effectiveness

Return on assets (ttm)-18.54%
Return on equity (ttm)-33.95%

Income statement

Revenue (ttm)2.81M
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)80.20%
Gross profit (ttm)N/A
EBITDA -15.74M
Net income avi to common (ttm)-15.76M
Diluted EPS (ttm)-0.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)30.7M
Total cash per share (mrq)N/A
Total debt (mrq)1.75M
Total debt/equity (mrq)4.51%
Current ratio (mrq)5.09
Book value per share (mrq)1.97

Cash flow statement

Operating cash flow (ttm)-12.73M
Levered free cash flow (ttm)-7.78M